Additional Results From Ongoing Phase 1 Study of Mivelsiran (ALN-APP) Presented at the Alzheimer’s Association International Conference (AAIC) 2024

31 Jul, 2024 Additional Results From Ongoing Phase 1 Study of Mivelsiran (ALN-APP) Presented at the Alzheimer’s Association International Conference (AAIC) 2024

Additional interim results from the single ascending dose part of the ongoing Phase 1 study of mivelsiran (ALN-APP), an investigational RNAi therapeutic in development for Alzheimer’s disease and cerebral amyloid angiopathy, were presented at the Alzheimer’s Association International Conference (AAIC) 2024.

Cohen, et al. “Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN-APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease”